Axcynsis Therapeutics
- Biotech or pharma, therapeutic R&D
Axcynsis Therapeutics develops antibody-drug conjugates (ADCs) utilizing our first-in-class ADC payload platform. Raising $40M series A. Out-licensing platform and select assets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}